Top Markets
Coin of the day
Syntara Limited Syntara Limited

Syntara Limited

SNT
Kedudukan dalam Saham #28274
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to... Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
Harga Saham
$0.0183374
Modal Pasaran
$27.51M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
9.62%
Negara
AU
Perdagangan Syntara Limited (SNT)

Kategori

Sejarah pecahan saham untuk Syntara Limited (SNT)
Saham Syntara Limited (simbol: SNT) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Aug 20, 2026.
Satu saham SNT yang dibeli sebelum Aug 20, 2026 kini bersamaan dengan 0 saham SNT.
Senarai pecahan saham
Tahun Pecahan Gandaan Gandaan Kumulatif
Tidak cukup data untuk tarikh yang disediakan.
Pecahan saham untuk syarikat pesaing atau serupa